BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
SUBSCRIBE
BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
BullScope
No Result
View All Result
Home Bargains & Bubbles

Morgan Stanley: Record Earnings, a Stock Up 47% in a Year, and a Multiple That Still Sits Below Its Own History

Moe Alsumidaie, MBA, MSF by Moe Alsumidaie, MBA, MSF
August 17, 2026
in Bargains & Bubbles
0
74
SHARES
1.2k
VIEWS
Share on XShare on LinkedInShare on Facebook

In one breath

Morgan Stanley’s filed numbers show the best earnings per share in at least five years, a return on equity that rivals the firm’s pre-crisis peak, and a capital cushion well above regulatory minimums. The stock has risen 47% over the past twelve months, yet its price-to-earnings multiple, the price tag per dollar of annual profit, sits below its own decade median. Those two facts cannot both be fully right, and the gap between them is the story.

Two numbers that shouldn’t share a sentence

Morgan Stanley’s stock trades at roughly 17.6 times trailing earnings, according to our data, just a whisker above the firm’s own decade median of 16.7 times. That gap is narrow, almost unremarkable. Now hold that against the other number: the stock is up 47% over the past twelve months, a move that usually signals a market convinced a business has re-rated permanently upward. A surge of that size landing at a below-median multiple means the earnings grew faster than the price. That is the contrast worth examining.

The math, our shorthand for what filed fundamentals justify, and the mood, what the market is currently paying, are unusually close right now. Whether that closeness reflects fair value or a lull before another leg is the open question this piece works through.

How the firm got here

Morgan Stanley spent most of the decade after 2008 rebuilding its identity. When the financial crisis hit, the firm converted to a bank holding company in September 2008, a move that gave it access to Federal Reserve funding but also permanently changed its cost structure and regulatory obligations. Its stock collapsed that year. Mitsubishi UFJ then injected $9 billion for a meaningful stake in October 2008, providing the capital floor the firm needed to survive.

BullScope TerminalWant the full evidence sheet behind pieces like this?The terminal runs the complete workup: Morgan Stanley and 500+ other names, on the same official data.See the evidence engine →

The strategic answer to that near-death experience was a slow pivot toward businesses that earn fees rather than take risk. Wealth management, where the firm collects a percentage of client assets regardless of whether markets go up or down, became the anchor. The E*TRADE acquisition, closed in 2020, pushed client assets toward the trillions and cemented that direction. The firm that nearly failed in 2008 is now, in 2026, posting the highest earnings per share in its modern history. That arc matters because it explains why the multiple has been compressed for years: investors spent a long time waiting to see whether the transformation was real.

What the Q2 2026 filing actually shows

The 10-Q for the quarter ended June 30, 2026, filed August 4, shows net revenues of $21.3 billion for the quarter, a record. To put that in human terms: the firm earned more in three months than many large industrial companies earn in a full year. Net income and diluted earnings per share both came in at records as well, as announced July 15, 2026.

The segment breakdown tells a specific story. Institutional Securities, the trading and advisory arm, was the standout, with equities trading alone setting a record for that line. Think of equities trading as the firm acting as a middleman for large investors buying and selling stocks: when markets are active and volatile, that middleman earns more. Wealth Management contributed a large and steadier, fee-driven complement. The two engines are running simultaneously, which is unusual and worth noting.

Return on equity, the profit the firm earns for every dollar its shareholders have put in, reached 20.7% for the quarter. A household savings account earns perhaps four to five percent right now. A return of more than twenty percent on the equity base is the kind of number that, if sustained, justifies a premium multiple over book value.

The capital picture: fortress or fully deployed?

Banks are required by regulators to hold capital as a buffer against losses. Morgan Stanley’s Common Equity Tier 1 ratio, the core measure of that buffer, stood well above the regulatory minimum as of June 30, 2026, per the same 10-Q filing. The firm is carrying nearly twice the required cushion, which limits the risk of a forced capital raise but also means the firm is holding capital that isn’t earning a return. The firm’s announced $20 billion share buyback plan, reported by MarketBeat as of August 15, 2026, is one way to deploy that excess, and management’s willingness to buy back stock at current prices is itself a signal about how they read their own valuation.

BullScope TerminalYou just read Morgan Stanley’s filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →

Reading the numbers

Diluted EPS, FY2025: $10.21. This is the total profit per share for the full year ended December 31, 2025, from the 10-K filed in 2026. It compares to $7.95 in FY2024 and $5.18 in FY2023, our data shows. That trajectory, from $5.18 to $10.21 in two years, is the single most important filed fact in this piece. A household that doubled its income in two years would look very different to a mortgage lender than it did before.

P/E ratio, trailing twelve months: 17.6x, our data. This is the price tag per dollar of annual profit. At 17.6x, a buyer of the stock today is paying $17.60 for each dollar Morgan Stanley earned over the past year. The firm’s own decade median is 16.7x, per our data, meaning today’s price is modestly above the historical norm but not dramatically so. For comparison, Simply Wall St noted in August 2026 that the broader Capital Markets industry trades at a median closer to 37 times earnings, suggesting Morgan Stanley carries a significant discount to its sector even at today’s price.

Price-to-tangible-book-value: 4.1x. Tangible book value is what the firm would theoretically be worth if it sold all its hard assets and paid off its debts, excluding intangible items like goodwill. At 4.1 times that figure, per our data calculated against the Q2 2026 filing‘s tangible book value per share of $53.18, the market is paying a substantial premium over liquidation value. That premium is only justified if the firm keeps earning at or above its current return on equity. If that 20.7% ROE reverts toward historical norms, the math supporting a 4x tangible book multiple gets harder to defend.

Q2 2026 equities trading revenue: $6.3 billion. This is a record for a single quarter, per Economy Insights reporting on the Q2 results. Trading revenue is the most volatile line in the business: it rises when markets are active and falls sharply in quiet or stressed periods. A saver evaluating the firm’s earnings power should ask how much of the current EPS run-rate depends on this line staying near record levels.

The open question the math cannot answer: how much of the current earnings level is structural, meaning it persists through a quieter market cycle, and how much is cyclical, meaning it fades when trading volumes normalize. The filed numbers show what happened. They do not guarantee repetition.

Sources

  • Morgan Stanley 10-Q, quarter ended June 30, 2026, SEC EDGAR
  • Morgan Stanley 10-K, fiscal year ended December 31, 2025, SEC EDGAR
  • Morgan Stanley Q2 2026 earnings release, SEC EDGAR, July 15, 2026
  • Economy Insights, Morgan Stanley Q2 2026 revenue coverage
  • MarketBeat, Morgan Stanley analyst consensus, August 15, 2026
  • Simply Wall St, Morgan Stanley valuation commentary, August 2026
  • MUFG press release, Morgan Stanley investment, October 2008
  • The Brand Hopper, Morgan Stanley strategic history
BullScope publishes impersonal research for a general audience. Nothing here is personalized investment advice, and nothing here is a recommendation to buy or sell any security. As of publication, neither BullScope nor its operator holds a position in any security, covered or otherwise; we do not trade at all, and we accept no compensation from any company we cover. When a conflict of interest exists, we do not publish: companies that compensate our operator in any capacity, or about which our operator could hold nonpublic information, are barred from coverage automatically, as described in the conflicts policy in our methodology. Figures come from company filings and public data through our published methodology; forecasts are conditional scenarios, not predictions and not promises. Markets carry risk, including loss of principal. Consider your own situation, or consult a licensed adviser, before acting on anything you read.
BullScope TerminalYou just read Morgan Stanley’s filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →
Moe Alsumidaie, MBA, MSF

Moe Alsumidaie, MBA, MSF

Moe Alsumidaie, MBA, MSF is the Chief Editor of BullScope. Trained in finance, with a Master of Science in Finance and an MBA, he spent years inside large public healthcare companies including Abbott, Genentech, and Roche, learning how the businesses behind the filings actually run. As a journalist and Chief Editor of The Clinical Trial Vanguard, his reporting has appeared in Applied Clinical Trials, The American Journal of Managed Care, and CNET, and has been cited in U.S. Supreme Court proceedings. At BullScope he brings those disciplines together: every note starts in the SEC filings, runs through published methodology, and shows its work.

Recommended For You

Halozyme: The Royalty Machine Trading at a Premium to Its Own History

by Moe Alsumidaie, MBA, MSF
September 9, 2026
0

Six years ago, Halozyme Therapeutics was a mid-sized biotech with a clever idea and a thin income statement. The idea was ENHANZE, a drug-delivery technology that dissolves the...

Read moreDetails

Merck Is Printing Money and Losing Money at the Same Time. Both Are True.

by Moe Alsumidaie, MBA, MSF
September 7, 2026
0

A trailing price-to-earnings ratio of 120 sits next to a price-to-sales ratio near its highest point in a decade. Those two numbers describe the same stock on the...

Read moreDetails

A $2.4 Billion Question: What Sarepta’s Filed Numbers Actually Say

by Moe Alsumidaie, MBA, MSF
September 3, 2026
0

The gist of it Sarepta's filed numbers tell a story of a company that briefly turned profitable in 2024, then swung back to a loss in 2025 after...

Read moreDetails

The Quiet Compounder at a Loud Price: What Royalty Pharma’s Filings Actually Say

by Moe Alsumidaie, MBA, MSF
September 2, 2026
0

Royalty Pharma's stock sat at an all-time low in December 2024. By late August 2026, it had touched an all-time high above $62. That is a gain of...

Read moreDetails

Half the Price, Same Business: What Zoetis’s Filed Numbers Actually Say

by Moe Alsumidaie, MBA, MSF
August 31, 2026
0

Two years ago, Zoetis traded at roughly 35 times its annual earnings. Today it trades at roughly 12 times. The revenue line has kept growing. The margin line...

Read moreDetails
Next Post

Starbucks Is Earning More Per Customer Than It Has in Years. The Stock Is Priced as If That's Just the Beginning.

Please login to join discussion
BullScope
The Research Terminal
Run any stock through the BullScope evidence engine. Filings in, evidence out. Every number explains itself.
Open the Terminal
A BullScope product

Related News

One drug carries the revenue. The next one just got complicated.

September 2, 2026

Morgan Stanley: Record Earnings, a Stock Up 47% in a Year, and a Multiple That Still Sits Below Its Own History

August 17, 2026

PepsiCo: The Stock Is Priced for Doubt. The Filing Tells a Different Story.

August 5, 2026
BullScope

BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.

Prefer BullScope.ai on Google

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

No Result
View All Result
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

Not enough quota to unlock this post
Unlock left : 0
Are you sure want to cancel subscription?
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.